Titre :

Nilotinib efficacy and safety as salvage treatment following imatinib intolerance and/or inefficacy in steroid refractory chronic graft-versus-host-disease (SR-cGVHD): a prospective, multicenter, phase II study on behalf of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC).

Auteur(s) :

Srour, Micha [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Alsuliman, Tamim [Auteur]
CHU Saint-Antoine [AP-HP]
Labreuche, Julien [Auteur]
Institute for Translational Research in Inflammation - U 1286 [INFINITE]
Bulabois, Claude-Eric [Auteur]
Centre Hospitalier Universitaire [CHU Grenoble] [CHUGA]
Chevallier, Patrice [Auteur]
Centre Hospitalier Universitaire de Nantes = Nantes University Hospital [CHU Nantes]
Daguindau, Etienne [Auteur]
Hôpital JeanMinjoz
Forcade, Edouard [Auteur]
Centre Hospitalier Universitaire de Bordeaux [CHU Bordeaux]
François, Sylvie [Auteur]
Centre Hospitalier Universitaire d'Angers [CHU Angers]
Guillerm, Gaelle [Auteur]
Centre Hospitalier Régional Universitaire de Brest [CHRU Brest]
Coiteux, Valerie [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Turlure, Pascal [Auteur]
CHU Limoges
Beguin, Yves [Auteur]
Centre Hospitalier Universitaire de Liège [CHU-Liège]
Magro, Leonardo [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]

Titre de la revue :

Bone Marrow Transplantation

Nom court de la revue :

Bone Marrow Transplant

Date de publication :

2023-01-10

ISSN :

1476-5365

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

Imatinib is used for patients with SR-cGVHD. However, in 50% of cases imatinib is discontinued due to intolerance or inefficacy. In order to investigate nilotinib’s role as salvage therapy in those patients, we conducted ...
Lire la suite >Imatinib is used for patients with SR-cGVHD. However, in 50% of cases imatinib is discontinued due to intolerance or inefficacy. In order to investigate nilotinib’s role as salvage therapy in those patients, we conducted a prospective, multicenter, phase II study. (NCT02891395). Patients with SR-cGVHD were included to receive imatinib. Patients who stopped imatinib due to intolerance or inefficacy switched to Nilotinib. The primary endpoint was defined as the week-12 response rate to Nilotinib. The response was considered successful if superior to the 30% endpoint. Sixty-two patients started the IM-phase. Fourteen patients (22%) discontinued imatinib before week 12 due to: cGVHD progression (10%) or TKI-class-specific intolerance (12%). At week 12, we observed complete remission in 13 patients (21%) and partial response in 8 patients (13%). Twenty-nine patients switched to Nilotinib. Nilotinib response at week-12 was observed in 6 patients (21%) while 23 patients (79%) discontinued Nilotinib due to intolerance/cGVHD progression. The primary endpoint was not reached. This prospective study confirmed the efficacy of imatinib in patients with steroid refractory cGVHD. It failed to demonstrate the efficacy of nilotinib as a salvage therapy in patients who were intolerant/unresponsive to imatinib.Lire moins >

Langue :

Anglais

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

Université de Lille
CHU Lille

Collections :

• METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694

Date de dépôt :

2023-11-15T02:41:41Z
2024-03-28T13:35:39Z